Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Neurocrine Biosciences (NBIX) Stock Price
Media coverage about Neurocrine Biosciences (NASDAQ:NBIX) has trended somewhat positive on Monday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.9482354738681 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Traded Higher Than Its 50 Day Average – Modern Readers (modernreaders.com)
- Neurocrine Biosciences Inc (NBIX) Moves Above Ichimoku Cloud – Financial News Review (finnewsreview.com)
- Research Ratings: Xerox Corporation (XRX), Neurocrine Biosciences, Inc. (NBIX) – AppsforPCdaily (appsforpcdaily.com)
- The Neurocrine Biosciences’ (NBIX) “Outperform” Rating Reaffirmed at Cowen and Company (techkenyot.com)
- Neurocrine Biosciences (NBIX) Receives Media Sentiment Rating of 0.26 (famososartistas.com)
Neurocrine Biosciences (NBIX) traded down 0.02% during mid-day trading on Monday, reaching $52.82. 695,268 shares of the company’s stock traded hands. Neurocrine Biosciences has a 12-month low of $37.35 and a 12-month high of $55.38. The company’s market cap is $4.66 billion. The stock has a 50 day moving average of $50.23 and a 200 day moving average of $47.62.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The business had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same quarter in the prior year, the firm earned ($0.46) EPS. On average, equities research analysts predict that Neurocrine Biosciences will post ($2.45) earnings per share for the current fiscal year.
NBIX has been the topic of a number of recent research reports. Barclays PLC upped their price target on shares of Neurocrine Biosciences from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, May 2nd. Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday. Cowen and Company restated an “outperform” rating and set a $65.00 price target (up from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, Bank of America Corporation initiated coverage on shares of Neurocrine Biosciences in a research note on Friday, May 5th. They set a “buy” rating and a $70.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have issued a buy rating to the company’s stock. Neurocrine Biosciences currently has an average rating of “Buy” and a consensus target price of $68.25.
COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/28/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-neurocrine-biosciences-nbix-stock-price.html.
In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 15,354 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $55.00, for a total value of $844,470.00. Following the transaction, the insider now owns 123,045 shares in the company, valued at approximately $6,767,475. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Haig P. Bozigian sold 22,500 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $50.00, for a total value of $1,125,000.00. Following the completion of the transaction, the insider now owns 154,601 shares in the company, valued at approximately $7,730,050. The disclosure for this sale can be found here. Insiders sold a total of 46,588 shares of company stock worth $2,406,170 in the last 90 days. 4.80% of the stock is currently owned by insiders.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.